Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (131)	11/19/2006 9:09:37 PM
From: tuck	Read Replies (1) \| Respond to of 210

>>The course of treatment for refractory GIST is shorter than myeloma?<< Could be; I have no idea. >>wiw, Infinity once listed in a press release Gleevec resistant GIST Herceptin resistant breast cancer Tarceva resistant lung cancer Velcade resistant multiple myeloma<< Thanks for that list; they are talking only monotherapy for all of those, right (though we now know monotherapy isn't feasible in MM)?. >>I am curious which trials would enroll the fastest.<< I haven't a clue. >>Maybe Perkins said what she said simply because Infinity has a partner in Medimmune, but Kosan does not. << Well, that seems a stretch to me, if so. That's more a difference in partnering strategy; if the companies have similar expertise (hard to assess if INFI/MEDI's clinical development expertise in oncology is better than Kosan's, and if so, what difference it will make before Kosan partners) and sufficient resources, the partner won't affect the clinical development timeline that much. KOSN raised funds recently, so they can afford to partner later than Infinity did, thus capturing more of the profits. I was asking if INFI has outlined the strategy by which they'll get to market first or if it's still a secret (though again, the only plausible way, IMO, is to register from GIST PII). Traveling again; may be out of touch for a couple of days. Happy Thanksgiving all! Cheers, Tuck